ArticleMediterranean journal of rheumatology2025
The Effectiveness of Infliximab in Treating Vascular Manifestations of Behçet's Disease: A Systematic Review and Meta-Analysis.
Article in Mediterranean journal of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From inflammation to rupture: advances in the pathogenesis of pseudoaneurysm formation in Vascular Behçet's Disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Our study aims to evaluate the effectiveness of anti-tumour-necrosis-factor Infliximab (IFX) in treating patients with severe and/or refractory vascular manifestations of Behçet's disease (BD) through a systematic review and meta-analysis. Methods: We searched PubMed, Scopus, Web of Science, and Cochrane Library databases for eligible studies. Meta-analysis of proportions was performed. Heterogeneity was assessed with Cochrane's Q test and I Results: Of the 2127 results initially identified, 11 studies with a total of 284 patients were included in the final analysis. Infliximab induced complete vascular response in 78.17% of patients (95% CI 63.11-90.61). The remission rates in the subgroups of patients with pulmonary artery aneurysm and the venous thrombosis events were respectively 99.13% (95% CI 86.21-100) and 86.48 % (95% CI 71.81-97.15). Conclusion: Our systematic review and meta-analysis support the use of infliximab in patients with severe and/or refractory vascular Behçet's disease, particularly in cases involving pulmonary artery aneurysms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.